Ep. 121: Avapritinib vs Placebo in Indolent Systemic Mastocytosis - PIONEER Trial
Part of the series: The Itch Review
LISTEN TO EPISODE 121: Apple Podcast • Spotify• Amazon Music
This podcast was made in partnership with Allergy & Asthma Network.
We thank Blueprint Medicines for sponsoring this episode. While they support the show, all opinions are our own, and sponsorship doesn’t influence our content or editorial decisions. Any mention of brands is for informational purposes and not an endorsement.
What happens when you target the root cause of indolent systemic mastocytosis?
In this episode of The Itch Review, we unpack key findings from the article “Avapritinib versus Placebo in Indolent Systemic Mastocytosis,” published on May 23, 2023, in NEJM Evidence.
Indolent Systemic Mastocytosis (ISM) is a rare chronic disease with life-altering symptoms. Until recently, treatment options were limited. We break down new data from Part 2 of the PIONEER study, which evaluated Avapritinib, a targeted therapy designed to inhibit the KIT D816V mutation that drives ISM.
Dr. Gupta and Dr. Blaiss explain how Avapritinib works, how the study was designed, and what outcomes were measured, including the Total Symptom Score (TSS). Most importantly, we explore what this treatment could mean for patients with moderate to severe ISM.
What we cover in our episode about avapritinib versus placebo:
Understanding ISM: How the KIT D816V mutation causes overproduction and overactivation of mast cells.
Why current treatment falls short: The limitations of best supportive care and why many patients remain symptomatic despite multiple medications.
How Avapritinib works: A tyrosine kinase inhibitor that targets the KIT mutation directly, aiming to reduce mast cell activation at its source.
Inside the PIONEER trial: Study design, eligibility criteria, and how outcomes like Total Symptom Score (TSS) and serum tryptase were measured.
What the data showed: Improvements in symptoms, lab markers, and quality of life and what this could mean for long-term ISM care.
The Itch Review - Avapritinib versus Placebo Infographic
The Itch Review, hosted by Dr. Gupta, Kortney, and Dr. Blaiss, explores allergy and immunology studies, breaking down complex research in conversations accessible to clinicians, patients, and caregivers. Each episode provides key insights from journal articles and includes a one-page infographic in the show notes for easy reference.
Timestamps
Our episode reviews part two of the PIONEER Trial looling at the medication avapritinib for ISM
01:20 Overview of indolent systemic mastocytosis (ISM)
03:55 Common symptoms experienced by ISM patients
05:06 Best supportive care for ISM
07:17 Avapritinib as a disease-modifying therapy
12:02 Description of Part 2 of the PIONEER study
13:43 Explanation of the Total Symptom Score (TSS)
15:25 Patient eligibility and enrollment criteria
18:20 Key elements of the study design
21:57 Patient randomization and 2:1 treatment allocation
25:38 Stratification based on tryptase levels
27:50 Primary outcomes measured in the study
28:57 Interpretation of the p-value and statistical significance
30:46 Summary of secondary endpoints
33:25 Safety findings and adverse event profile
36:17 Final takeaways and clinical implications
